An interventional study of Blood draw for biomarkers in Chronic Liver Disease (CLD) and Fibrosis of Liver, sponsored by Universitair Ziekenhuis Brussel. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Universitair Ziekenhuis Brussel · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Liver Cirrhosis with a site in Belgium — 11 open to participants now, 13 under way, 2 of them phase 3. Liver Cirrhosis · Belgium.
Among the 41 studies in Liver Cirrhosis with a site in Belgium, this one is the 15th largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 39th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →11 of the 41 studies in Liver Cirrhosis with a site in Belgium are open now. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Belgium, Austria, Czechia and 9 more countries
Ages 18+
Universitair Ziekenhuis Brussel · Sites in Belgium
Ages 18+
Centre Hospitalier Universitaire Saint Pierre · Sites in Belgium
Ages 18+
Boehringer Ingelheim · Sites in Belgium, United States, Argentina and 34 more countries
Ages 18+
Julius Clinical · Sites in Belgium, Czechia, France and 7 more countries
Ages 18–75
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 12 · Phase 3 9 · Phase 4 2
First in 2000; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is above the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 159 across the 24 interventional studies, 450 across the 17 observational. Of the 25 that completed or were terminated, 6 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 41 have an industry lead sponsor. The 10 most frequent:
Universitair Ziekenhuis Brussel is the lead sponsor of 375 studies on the registry; 107 are open to participants now.
Universitair Ziekenhuis Brussel has 2 studies filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Liver Cirrhosis with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT07585890University Medical Center GroningenEstablishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT07238114Universitaire Ziekenhuizen KU LeuvenLiver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors | 2027-07-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 41 studies in Liver Cirrhosis with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Morbidity and mortality of CLD is driven by the extent of liver fibrosis, characterized by scar formation and disruption of the normal liver architecture. HSCs play a central role in liver fibrosis development. When hepatocytes are damaged, HSCs undergo myofibroblast differentiation, transitioning into an activated state. So far, no efficient biomarkers can estimate the degree of HSC activation or reversal across all aetiologies of CLD, although this could be a more sensitive marker than fibrosis measurement which is secondary to HSC activation. This study aims to correlate biomarkers to the fibrosis stage in a larger cohort of patients with CLD across all aetiologies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Blood draw for biomarkers
EDTA tube Blood draw for biomarkers
correlation of biomarkers in blood and fibrosis stage of liver
correlation of biomarkers in blood and fibrosis stage of the liver (comparison with: transient elastography, fib4, APRI and liver biopsy if possible)
Time frame: Day 1 of the study
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Jan 2028, 20 months later.
Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 20 months is below that.
Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitair Ziekenhuis Brussel →